164
Participants
Start Date
February 14, 2019
Primary Completion Date
November 10, 2020
Study Completion Date
October 29, 2025
Patisiran
Patisiran will be administered by IV infusion.
Vutrisiran
Vutrisiran will be administered by SC injection.
Clinical Trial Site, New York
Clinical Trial Site, Philadelphia
Clinical Trial Site, Baltimore
Clinical Trial Site, Chapel Hill
Clinical Trial Site, Columbus
Clinical Trial Site, Rochester
Clinical Trial Site, Fort Worth
Clinical Trial Site, Aurora
Clinical Trial Site, San Diego
Clinical Trial Site, Chicago
Clinical Trial Site, Portland
Clinical Trial Site, Boston
Clinical Trial Site, Buenos Aires
Clinical Trial Site, Box Hill
Clinical Trial Site, Westmead
Clinical Trial Site, Woolloongabba
Clinical Trial Site, Brussels
Clinical Trial Site, Leuven
Clinical Trial Site, Rio de Janeiro
Clinical Trial Site, Sofia
Clinical Trial Site, Montreal
Clinical Trial Site, Vancouver
Clinical Trial Site, Nicosia
Clinical Trial Site, Bordeaux
Clinical Trial Site, Créteil
Clinical Trial Site, Marseille
Clinical Trial Site, Paris
Clinical Trial Site, Mainz
Clinical Trial Site, Münster
Clinical Trial Site, Athens
Clinical Trial Site, Messina
Clinical Trial Site, Milan
Clinical Trial Site, Pavia
Clinical Trial Site, Rome
Clinical Trial Site, Aichi
Clinical Trial Site, Kumamoto
Clinical Trial Site, Nagano
Clinical Trial Site, Nagoya
Clinical Trial Site, Osaka
Clinical Trial Site, Kuala Lumpur
Clinical Trial Site, Mexico City
Clinical Trial Site, Groningen
Clinical Trial Site, Lisbon
Clinical Trial Site, Porto
Clinical Trial Site, Junggu
Clinical Trial Site, Barcelona
Clinical Trial Site, Huelva
Clinical Trial Site, Madrid
Clinical Trial Site, Valencia
Clinical Trial Site, Solna
Clinical Trial Site, Umeå
Clinical Trial Site, Taipei
Clinical Trial Site, London
Lead Sponsor
Alnylam Pharmaceuticals
INDUSTRY